Transcript Highlights:

• Before that, we were seeing a lot of your normal pharmaceutical drugs, and then most of the tablets..
• drug of the same family, but much more potent and not being, you know, not being created by a pharmaceutical
• And so for a little while, we saw the regular pharmaceuticals start to come back.
• public would not notice the slight little differences that might be there between those and normal pharmaceutical

Summary: The committee met with representatives from the Arkansas State Crime Lab for what members said was likely the first appearance by the lab before this committee. Lab officials gave an overview of the new crime lab facility now under construction, saying it is on schedule, under budget, and expected to be completed by the end of July next year, with phased move-in beginning around August 1. They explained that the current building is over 40 years old and overcrowded, with caseloads having doubled over the past 20 years, and said the new facility will improve workflow, add morgue capacity, and allow new technologies and equipment to be brought online. Members asked about staffing and recruitment, and the lab said recent pay changes and legislative support have made Arkansas more competitive for forensic specialists and medical examiners. Officials said vacancies have been reduced, a new deputy chief medical examiner has been hired, two more medical examiners are starting in August, and a new fellowship program has already attracted applicants. They also said the lab is prepared for the staffing needs of the new facility and that training periods remain long for many analyst positions. The discussion also covered rapid DNA, CODIS, sexual assault kit processing, genetic genealogy, and overdose-related data sharing. The lab said rapid DNA is in final testing with pilot agencies in Faulkner and Saline counties and could go live by the end of July, which would make Arkansas among the first states to do so. Officials described CODIS as a key investigative tool, said DNA profiles are entered automatically when they qualify, and reported that the sexual assault kit backlog has been cleared with the lab now maintaining a 60-day turnaround. They also confirmed Arkansas uses a kit-tracking system, works with private labs such as Othram and Bode for genetic genealogy, and is developing an overdose dashboard to share toxicology and overdose data with public health and law enforcement partners. Members praised the lab’s progress and the committee adjourned after announcing an August site visit to Lake Conway and the dam project.

Transcript Highlights:

• Before that, we were seeing a lot of your normal pharmaceutical drugs, and then most of the tablets..
• drug of the same family, but much more potent and not being, you know, not being created by a pharmaceutical
• And so for a little while, we saw the regular pharmaceuticals start to come back.
• public would not notice the slight little differences that might be there between those and normal pharmaceutical

Keywords: 1204, all

Transcript Highlights:

• But given where we are today, given the reluctance of payers and providers and pharmaceutical companies
• The amendment excludes spending on pharmaceuticals, including medically administered drugs, from the
• Pharmaceutical costs reflect the price of a drug rather than a direct investment in primary care clinician
• It changes only how pharmaceutical expenditures are counted when calculating the statewide aggregate
• It changes only how pharmaceutical expenditures are counted when calculating the statewide aggregate

Keywords: 995, all

Summary: The Senate considered a series of amendments to a primary care health care bill and also took up a separate literacy bill. Several amendments were withdrawn, including one on artificial intelligence in health care and others related to cost controls, direct primary care, and provider studies. The Senate adopted amendments on preserving access to treatment for serious mental illness, modernizing the definition of primary care, clarifying payment rates for community health centers, excluding pharmaceutical spending from primary care expenditure calculations, and strengthening health equity reporting. Other amendments on rate bands, alternative payment systems, private equity reporting, scope of practice, and ownership disclosure were rejected. The Senate then approved the Ways and Means amendment and ordered the primary care bill to a third reading. The chamber also took up final passage of An Act Relative to Teachers Preparation and Student Literacy, with senators describing it as a long-awaited compromise focused on improving early reading outcomes. Supporters said the bill requires evidence-based K-3 literacy curricula, regular student screening and family notification, dyslexia screening protocols, professional development for teachers, and a free state-developed curriculum option. Senators emphasized the need to address declining third-grade reading proficiency and equity gaps. The bill passed to be enacted by a unanimous roll call and was sent to the Governor. After the literacy bill, the Senate returned to the primary care bill, where senators again debated cost containment, innovation, and access. The final version included the adopted amendments and was passed to be engrossed by a roll call vote of 35-4. The Senate then adopted an adjournment order and recessed, adjourning in memory of Henry Thomas III, former Representative Ben Swan, and Mr. Dennis Frane.

Transcript Highlights:

• , we are one of only two countries in the world that allow direct-to-consumer advertising for pharmaceuticals
• And you have people that are hearing these ads from the pharmaceutical companies claiming their vaccines
• are safe, incentivized. ...these ads from the pharmaceutical companies claiming their vaccines are safe
• We hear disclaimers at the end of general pharmaceutical commercials, sometimes all the potential side
• The pharmaceutical companies can educate doctors.

Bills: S0408, S0986, S0678, S0800, S1050, S0484, S1118

Keywords: vaccine advertisement, manufacturer liability, harmful vaccine, healthcare, court action, smoking regulation, public health, vaping, marijuana, public places, Florida Statutes, alcohol distribution, tax deductions, extraordinary losses, warehouse breakage, regulatory compliance, veterinary, prescription, pharmacy, client rights

Summary: The Committee on Regulated Industries considered several bills and took final action on each. SB 986, by Senator Gruters and presented by Senator Rodriguez, would prohibit smoking or vaping marijuana in public places and in certain indoor spaces; restaurant and lodging representatives supported adding marijuana and vaping to clean indoor air rules but asked to preserve designated smoking areas on private property, while cannabis advocates warned the bill was overly broad and could affect patients and property rights. The committee voted the bill favorably. SB 678, by Senator Mayfield, would restore statutory authority for DBPR to continue allowing alcohol distributors to deduct unsellable alcohol from monthly excise tax calculations; the committee adopted a strike-all amendment and reported the committee substitute favorably. SB 800, also by Senator Mayfield, increases penalties for repeated unlicensed engineering practice and creates an engineering student loan assistance program for engineers working for state agencies and water management districts; after adopting an amendment clarifying eligibility, the committee reported the bill favorably. The committee then heard SB 408, by Senator Grall, which would create a Florida cause of action against vaccine manufacturers that advertise in the state, allowing injured individuals to sue in Florida courts. Supporters argued the bill would rebuild public trust and hold manufacturers accountable, while opponents from the Florida Justice Reform Institute, American Tort Reform Association, BIO, the U.S. Chamber Institute for Legal Reform, and several medical and business groups argued the field is largely preempted by federal law, that existing federal compensation programs already address vaccine injuries, and that the bill raises First Amendment and policy concerns. After debate focused on vaccine injury data, compensation rates, and liability, the committee voted SB 408 favorably. The committee also considered SB 484 and SB 1118, both by Senator Avila, dealing with data centers. SB 484 would preserve local planning authority, bar nondisclosure agreements that prevent disclosure of potential data center development, require the PSC to set large-load tariff requirements so data centers pay their own costs, and limit consumptive use permits for large-scale data centers absent no harm to water resources and compliance with local zoning; supporters emphasized ratepayer protection and economic development, while some witnesses urged flexibility for behind-the-meter projects and confidentiality in negotiations. The bill was reported favorably. SB 1118 would create a time-limited public records exemption for county or municipal information about data center siting and protect proprietary business information; Senator Pizzo raised concerns about how the exemption would affect disclosure of competing projects and local officials’ ability to speak, but the sponsor said he would work on clarifying the language. The committee also passed SB 1050, by Senator Calatayud, which requires veterinarians to provide pet owners with written prescriptions and information about pharmacy choice while preserving veterinary judgment and emergency dispensing authority. The meeting concluded after all bills were reported favorably and members recorded additional votes on prior items.

Transcript Highlights:

• It compounds it. Business applications are executed under penalty of perjury.
• It compounds it.
• Business applications are executed under penalty of perjury. compounds it business applications are executed
• We have the former Stewart Pharmaceutical building across the street from a transit-oriented development

Summary: The committee heard several housing, local government, coastal, and infrastructure bills. AB 306 would create a statewide appeal and code-interpretation process for building code issues at the California Building Standards Commission; supporters said it would reduce inconsistent local interpretations and speed housing delivery, while no opposition testified, and it was moved on a do-pass-as-amended vote to Appropriations. AB 956 would clarify ADU law to allow up to two detached ADUs on a property and address ADUs in HOAs/common interest developments; supporters framed it as a flexibility and housing-supply measure, while local government and county groups raised concerns about ministerial approval, parking, density, and impacts on neighborhood character. After committee questions, the bill was moved do pass as amended to Appropriations on a 2-0 vote, with the bill remaining on call. Members also considered AB 1751, which would create a ministerial approval path for qualifying townhome projects and allow local inclusionary ordinances for larger projects. Supporters said it would expand attainable homeownership and help produce missing-middle housing, while cities and counties objected to reduced density, by-right approval, and potential housing-element net-loss issues. The bill was moved do pass as amended to Appropriations on a 2-0 vote and remained on call. AB 912, which would revise the governance structure of the Vallejo Flood and Wastewater District board, drew unanimous support from the district, city, and county; it passed 3-0 to Appropriations and remained on call. AB 1710, aimed at preserving housing project entitlements from later regulatory changes, also advanced on a 4-0 do-pass-as-amended vote after opponents said they were awaiting the committee amendments. The committee also heard AB 2080, which would make county treasurer investment authority delegations ongoing until revoked rather than requiring annual renewal; supporters said it would reduce technical noncompliance and administrative burden without reducing oversight, and it was moved to the Senate Floor. AB 1740, a coastal bill for Santa Monica, would set timelines and reporting for a local coastal program and create an expedited Coastal Commission process for bike, transit, and pedestrian projects; supporters said it reflected a negotiated path forward with the city and commission, and it passed 3-0 to Appropriations. AB 2181, backed by Unite Here, would limit use of hypothetical density bonus value in hotel and motel appraisals; supporters said it would protect hospitality jobs from speculative lease-rent increases, and it was moved to the Senate Floor on a 4-0 vote. Finally, AB 2469 on data centers and water use drew the most extended debate. The bill would require water supply and water use assessments before approval, and shift infrastructure costs to project proponents; supporters said it would improve transparency, protect ratepayers, and ensure local governments have information before approving water-intensive facilities. Opponents, including business, city, county, and tech groups, argued existing law already covers water assessments and fees, warned the bill could create a separate permitting regime, and raised concerns about privacy, security, and investment impacts. The committee had not yet taken final action on AB 2469 when the transcript ended, and members were still asking technical questions about data center cooling and water reuse.

Transcript Highlights:

• EpiPens are pharmaceutical drugs.
• </c> prescribing pharmaceutical drugs? prescribing pharmaceutical drugs?
• EpiPens are pharmaceutical drugs.
• </c><02:17:02.319><c> like</c> considered a pharmaceutical drug like considered a pharmaceutical drug
• This is simply a disclosure bill to the patient. pharmaceutical companies spend hundreds pharmaceutical

Keywords: 1191, senate, all

Transcript Highlights:

• Hospital costs have increased by more than 265% over the last five years, and pharmaceutical costs have
• Hospital costs have increased by more than 265% over the last five years, and pharmaceutical costs have
• Chair and members, Alison Ramey on behalf of the Pharmaceutical Care Management Association, in support
• Currently, pharmaceutical companies often offer coupons to privately insured patients to provide discounts
• Since pharmaceutical companies can change the coupon programs and patient eligibility rules for those

Keywords: 988, house, all

Transcript Highlights:

• aircraft engines and parts, agricultural products like bourbon, beef, pork, and thoroughbred horses, pharmaceuticals
• aircraft engines and parts, agricultural products like bourbon, beef, pork, and thoroughbred horses, pharmaceuticals
• aircraft engines and parts, agricultural products like bourbon, beef, pork, and thoroughbred horses, pharmaceuticals
• , beef, pork, and thoroughbred bourbon, beef, pork, and thoroughbred horses,<00:33:07.919><c> pharmaceuticals
• </c> horses, pharmaceuticals, and machinery. horses, pharmaceuticals, and machinery.

Keywords: Convene 00:00 Senate Message 04:45 Calendar/2nd Readings 05:20 Report of Committees 07:05 Orders of the Day 08:23 HB 214 08:33 HB 416 12:26 HB 281 16:20 HB 134 18:13 Motions, Petitions, and Communications 21:08 Introduction of New Bills and Resolutions 37:01 Recess for ConC/Rules Meeting 39:15 ConC/Rules Report 42:29 Floor Amendments 44:27 Correction to Introduction of New Bills and Resolutions 46:14 Adjournment 46:40, 958, all

Transcript Highlights:

• know what the difference between, I guess, the whole leaf kratom and the 7-OH, like that active pharmaceutical
• what the difference between, I guess, the whole leaf cratum and the 708 for like that active pharmaceutical
• And the 7-OH, for like that active pharmaceutical ingredient, whatever that opioid is, do you know the
• concomitant use of other substances, including alcohol, opioids such as fentanyl, barbiturates, pharmaceuticals
• Can you give me what that ratio looks like for, you know, what that active pharmaceutical ingredient,

Keywords: 989, all

Summary: The House Health and Welfare Committee took up House Bill 864, which would classify kratom and related substances as Schedule I drugs. The bill’s sponsors, Representatives [name not fully captured in the transcript] and Aaron Bingham, argued that kratom is addictive and dangerous, citing reports from law enforcement, coroners, parents, and medical professionals about overdoses, deaths, withdrawal, and increasing use in Idaho. They also pointed to FDA warnings and materials suggesting kratom can cause opioid-like effects and that synthetic 7-hydroxymitragynine products are especially concerning. Testimony was sharply divided. Supporters of the bill included a drug and alcohol treatment provider, a county coroner, and a sheriff, who described rising kratom-related treatment admissions, deaths they attributed to kratom intoxication, youth access, and the difficulty of addressing the substance under current law. Opponents included retailers, consumers, a family physician, a toxicologist, and people with chronic pain, who argued that natural leaf kratom has helped many adults manage pain or reduce opioid use, that the real problem is synthetic or adulterated 7-OH products, and that a full ban would push use into the black market and create withdrawal problems for current users. Several witnesses urged a regulatory approach instead, such as age limits, labeling, testing, and restrictions on concentrated products. Committee members asked questions about the difference between natural leaf kratom and 7-OH, the scientific basis for the deaths discussed, and whether regulation could address the concerns without a total ban. Because many people had signed up to testify and time was limited, the chair stopped the hearing before all witnesses were heard and announced the committee would continue testimony the next day from 8 to 9 a.m. No vote on the bill was taken during this portion of the meeting.

Transcript Highlights:

• FIRST UP IS MICHAEL POWER, PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION AN OPPONENTS OF THE BILL WISHING
• CHAIRMAN THANK YOU, MY NAME IS MICHAEL POWER WITH THE PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION, THE
• IT IS NOT MY INDUSTRY BUT IT FEELS TO ME AMERICANS ARE JUST GETTING SHAFTED BECAUSE PHARMACEUTICAL COMPANIES
• COMMEND PRESIDENT DONALD TRUMP AND THE TRUMP ADMINISTRATION FOR AT LEAST TRYING TO FORCE THE PHARMACEUTICAL

Transcript Highlights:

• There is no current pharmaceutical or pharmacy expertise within the insurance department, so we would
• There is no current pharmaceutical or pharmacy expertise within the insurance department that we would
• be creating a new division within the insurance department that we would be. pharmaceutical or pharmacy
• So this was an attempt to say, okay, the pharmaceutical industry will have some skin in the game with

Keywords: 908, all

Summary: The Senate Committee on Industry and Business reconvened to work on House Bill 1584, which would create a new pharmacy benefit manager (PBM) regulatory structure within the Insurance Department. Insurance Commissioner John Godfrey and Deputy Commissioner John Arnold explained a revised set of amendments negotiated with Representative Casper and the North Dakota Pharmacists Association. They said the bill largely kept the House policy intact but added technical corrections, narrowed some references in Chapter 19-02, created a separate PBM licensing class, set a delayed effective date for licensing, and established emergency authority so the department could begin building the new division. They also described the proposal to fund the program through existing trust fund resources, PBM license fees, and a transfer of about $1.6 million from the prescription drug transparency program fund, while allowing the department flexibility to hire needed attorneys, pharmacists, and examiners. A major point of discussion was Section 10, which would have required the Attorney General to represent and bear costs for lawsuits related to the bill. Chief Deputy Attorney General Claire Ness said the language was too broad and would go beyond normal constitutional defense work, potentially obligating her office to cover all lawsuits against the commissioner or state under the section. Representative Casper said the intent was only to avoid the Insurance Department having to seek emergency funding for litigation, and both he and department officials said they were open to removing the section or narrowing it. After further discussion, the committee agreed to remove Section 10 from the amendments. The committee then voted 4-0 to adopt the amended amendment package, and then voted 4-0 to give House Bill 1584 a do pass recommendation as amended and refer it to Appropriations. Members noted the bill was still a work in progress, but said the revised version was intended to move the PBM regulation issue forward while continuing discussion in the appropriations process.

Transcript Highlights:

• We had a law, if you’ll go with me to page five, a standing law that said a lifetime ban on pharmaceutical
• There are two steps they have to take: the medical board to get their licensing back, but the pharmaceutical
• We had a law, if you’ll go with me to page five, a standing law that said a lifetime ban on pharmaceutical
• If you’ll go with me to page five, a standing law that said a lifetime ban on pharmaceutical licensees
• There are two steps they have to take: the medical board to get their licensing back, but the pharmaceutical

Keywords: 958, all

Summary: The committee first took up House Bill 90 / Senate Bill 17, a birth-related measure backed by the Kentucky Birth Coalition. Sponsors said the bill had been worked on for several years and described changes including a transfer agreement, insurance requirements, proximity to a hospital, informed consent, and accreditation/medical director standards that helped win neutral or non-opposition from the Hospital Association. The bill was reported favorably after a roll call vote with unanimous support. The committee then heard Senate Bill 65, presented by Senator Steve West and Representative Derrick Lewis. They said the bill would make regulations found deficient through the committee review process null and void by statute, and would bar agencies from reissuing the same or similar language for up to a year. Supporters argued this was needed to hold agencies accountable because deficiency findings alone had not led to action. After questions about specific Medicaid behavioral health regulations and concerns about legislative overreach, the bill passed the committee on a roll call vote, with some members passing or explaining reservations. Finally, the committee considered Senate Bill 84, with a House committee substitute. Sponsors said the substitute was intended to strengthen the bill and reflect the U.S. Supreme Court’s Loper Bright decision by ending Chevron deference and requiring courts, not agencies, to interpret law. Opponents, including Audrey Ernsberger and Katherine Hargraves, argued the bill would intrude on the judiciary, violate separation of powers, and could harm public health, environmental, and workplace protections. Committee members also raised concerns about whether the bill told courts what standard to use; sponsors responded that agencies could still present persuasive arguments, but courts should not defer to them. The committee substitute was adopted, and the bill then passed the committee on a roll call vote, with several members passing or expressing constitutional concerns.

Transcript Highlights:

• Vaccines, just like many other pharmaceutical products, are not one-size-fits-all.
• My career has been dedicated to diagnostics and pharmaceuticals.
• You have been hijacked by the big pharmaceutical companies.
• You worship pharmaceuticals like religion. It is insane. It is absolutely insane.
• Pharmaceutical companies, you have all become indoctrinated. It is shameful.

Keywords: 995, all

Summary: The Joint Committee on Public Health held a hearing on several vaccination-related bills, including proposals to eliminate non-medical or religious exemptions for school immunizations (notably H. 2554 and S. 1557), a bill to require or improve reporting and administration of immunization data and exemptions (described as the Community Immunity Act, S. 1618), and H. 2431, which would prohibit COVID-19, mRNA, or gene-altering vaccine requirements. The committee also heard testimony on H. 2463, which would classify funeral directors as public health workers for vaccine-priority purposes during emergencies. The chair reviewed testimony rules and repeatedly asked speakers to keep comments orderly and brief so the committee could hear as many people as possible. No votes were taken during the hearing. Testimony on H. 2554 and S. 1557 was sharply divided. Pediatricians, infectious disease specialists, public health advocates, and groups such as the Massachusetts Chapter of the American Academy of Pediatrics, Massachusetts Medical Society, March of Dimes, Massachusetts Families for Vaccines, and several parents supported eliminating religious exemptions, arguing that vaccination protects medically vulnerable children and adults, improves herd immunity, and helps prevent outbreaks of measles, pertussis, and other diseases. They cited local school data showing pockets of lower coverage and incomplete reporting, and several speakers referenced outbreaks in other states and the need for stronger, more consistent reporting and exemption management. Opponents argued the bills would infringe on religious freedom and parental rights, force families to choose between faith and education, and unfairly target a small number of families; some also said Massachusetts already has high vaccination rates and that the real issue is incomplete data or the gap population rather than religious exemptions. H. 2431 drew testimony from supporters who said COVID-era mandates caused job losses, privacy concerns, and harm, and that the bill would prevent future requirements for COVID, mRNA, or gene-altering vaccines in schools, workplaces, and public settings. Supporters described personal experiences with alleged vaccine injury or mandate-related hardship. H. 2463 was supported by the Massachusetts Funeral Directors Association, which argued funeral directors work in infection-facing settings and should be eligible for vaccine priority during public health emergencies. The hearing featured extensive public testimony but no committee action beyond hearing the bills and taking questions from members.

Transcript Highlights:

• Everyone benefited from the 340B savings program, but as the pharmaceutical companies tightened access
• And when you have specialty pharmaceuticals, you have to get, like, special cancer drugs.
• There's a standard pharmaceutical fee for dispensing, but the 340B savings go directly back into your
• Alison Ramey here this evening on behalf of the Pharmaceutical Care Management Association.
• And the reality is that you have a market where you have big monopolies, pharmaceutical companies, who

Summary: The Assembly Health Committee met on April 22 and took up a special order of bills focused largely on prior authorization and utilization management in health care. The chair framed the discussion as part of a broader legislative effort to reduce delays and barriers to care, especially in behavioral health, chronic disease management, cancer treatment, and rehabilitation services. AB 384 by Assembly Member Connolly would prohibit prior authorization for inpatient mental health or substance use emergency admissions and related physician care; supporters said it would prevent dangerous delays in crisis care, while insurers and health plans warned about fraud, abuse, and ambiguity around residential treatment facilities. The bill was moved on a due pass as amended motion and passed the committee on a party-line style vote, with Republicans largely absent or not voting. The committee then heard AB 510 by Assembly Member Addis, which would require health plans, upon request, to provide a peer reviewer of the same or similar specialty when a treating provider appeals a prior authorization denial or modification. Supporters argued that specialty-matched review would make appeals fairer and more clinically informed; opponents said the requirement was too rigid and that timelines and electronic submission rules needed changes. After discussion about the need for timely, specialty-specific review, the bill was approved on a due pass as amended motion and placed on call. AB 539 by Assembly Member Schiavo would extend prior authorization approvals to one year or the duration of the physician’s prescribed treatment for chronic conditions; supporters cited repeated denials and treatment interruptions, while opponents raised concerns about overbreadth, fraud, and the need for shorter validity periods. The bill was also passed as amended and placed on call. The committee next considered AB 669 by Assembly Member Haney, which would bar concurrent and retrospective review for the first 28 days of medically necessary substance use disorder treatment and limit prior authorization for related outpatient medications. The bill was presented with a powerful personal story from Ryan Matlock’s mother about her son’s death after an insurer cut off treatment early; supporters said the measure would keep patients in care long enough to stabilize, while opponents argued it would reduce oversight and could allow lower-quality or non-evidence-based care. The bill was moved on a due pass as amended motion and placed on call. Finally, AB 512 by Assembly Member Harabedian would shorten prior authorization response times to 24 hours for urgent requests and 48 hours for non-urgent requests; supporters said delays can worsen outcomes, while opponents warned the timelines were unrealistic and could increase administrative burdens and safety issues. The bill was approved as amended and placed on call. AB 574 by Assembly Member Mark Gonzalez was then heard; it would allow up to 12 medically necessary physical therapy sessions for a new episode of care without prior authorization, with supporters emphasizing stroke and neurological recovery and opponents warning of reduced oversight and unnecessary care. The transcript ends during testimony on AB 574, before final action is shown.

Transcript Highlights:

• its place we are adding the provisions of Senate Bill 14, which prohibits discrimination by a pharmaceutical
• 02:51.480><c> a</c> prohibits the Discrimination uh by a prohibits the Discrimination uh by a pharmaceutical
• that it was established but it um 90s that it was established but it um allows<00:05:47.080><c> pharmaceutical
• </c><00:05:47.800><c> manufacturers</c><00:05:48.759><c> to</c> allows pharmaceutical manufacturers to
• allows pharmaceutical manufacturers to sell<00:05:50.240><c> products</c><00:05:50.680><c> sell</c><

Keywords: 00:25 Call to Order/Roll Call 01:36 Discussion of 25RS SB 153 23:11 Roll Call Vote on 25RS SB 153 30:56 Adjournment, 958, all

Summary: The House Standing Committee on Health Services met on March 14, 2025, and took up a committee substitute for Senate Bill 153. The substitute deleted the original bill language and replaced it with provisions from Senate Bill 14, aimed at prohibiting pharmaceutical manufacturers from discriminating against 340B covered entities and adding reporting requirements for those entities. The sponsor explained that the protections would sunset after one year, allowing lawmakers to review data by July 1, 2026, and that Kentucky would continue to follow any future federal changes to the 340B program. Members asked several questions about the scope of the reporting, including what “total operating cost” means, how duplicate discounts are prevented, whether the reporting applies only to hospitals and not federally qualified health centers, and who would receive the data. The sponsor said the reporting is intended to help the Cabinet for Health and Family Services and the Office of Health Data Analytics at LRC assess how the program is working, including charity care and community benefits, while preserving protections for rural hospitals and allowing them to continue using contract pharmacies. A representative from LRC confirmed the data would come to the General Assembly through the Office of Health Data Analytics. The committee expressed mixed views about the balance between transparency and potential burdens on hospitals, especially rural facilities. Several members said they were supportive but had reservations about the reporting requirements and the sunset structure, while others noted concerns about unintended consequences and the possibility of changes on the House floor. The committee ultimately adopted the committee substitute, approved a title amendment, and reported Senate Bill 153 with House Committee Substitute 2 favorably. The meeting then adjourned.

Transcript Highlights:

• That's not how we regulate aviation, it's not how we regulate pharmaceuticals, and it should not be how
• These regulations compound this problem by keeping the public in the dark.

Keywords: 988, house, all

Transcript Highlights:

• universities, cutting-edge research institutions, skilled workers, and a growing base of biotechnology, pharmaceutical
• Cutting-edge research institutions, skilled workers, and a growing base of biotechnology, pharmaceutical
• Under current law, a pharmaceutical or medical device manufacturer must first complete the lengthy federal
• Under current law, a pharmaceutical manufacturer must complete the full federal FDA approval process

Summary: The Senate convened with prayer and the Pledge of Allegiance, received committee reports, and approved the prior day’s journal by a 50-0 vote. Several members were granted leaves of absence, and the chamber also took up a number of procedural motions, including re-referring Senate Bill 1212 to Appropriations and moving Senate Bill 911 from the table to the calendar. The Senate later recessed for committee meetings and party caucuses, then reconvened to continue floor action. On the calendar, Senate Bill 1206 passed 50-0 after supporters said it would help Pennsylvania’s life sciences industry by allowing manufacturers to pursue state licensure while federal FDA approval is pending, without weakening safety standards. Senate Bill 1273 passed 48-2; its sponsor said it would clarify that turnpike automated plate-reading data may be shared with investigators in missing or endangered persons cases, including Amber Alerts. Several other bills were either agreed to and re-referred to Appropriations or ordered over in their place, including House Bill 681, Senate Bills 1061, 1303, and 1355, and House Bill 1505 and 1667. The Senate also considered Senate Resolution 326, where an amendment by Senator Mastriano was adopted and the resolution was then held over as amended. In executive session, the chamber returned several nominations to the governor, then confirmed a slate of gubernatorial nominations, including appointments to the Pennsylvania Drug, Device, and Cosmetic Board, the State Board of Osteopathic Medicine, and several Pennsylvania Army National Guard promotions, by a 50-0 vote. The Senate additionally approved committee-reported bills from Appropriations and Health and Human Services, and signed House Bill 1344 in the presence of the Senate. During petitions and remonstrances, Senator Tartaglione urged action on minimum wage legislation, noting Pennsylvania has not raised the wage since 2006 and pointing to House Bill 2189. Senator Dush delivered extended remarks on the nation’s founding and the religious views of Benjamin Franklin. The Senate then adopted a motion to recess until June 25, 2026, at 9:30 a.m., unless recalled sooner.

Transcript Highlights:

• First, we are concerned with the language regarding pharmaceutical advertising.
• is clear that the intent of these provisions is intended to prescribe the behavior of pharmaceutical
• Enforcement of these provisions should therefore be targeted only at pharmaceutical companies.
• As a practical matter, compliance responsibility should rest solely with pharmaceutical companies who
• Again, if the intent of the bill is to prescribe pharmaceutical ads, then the bill should prevent the

Keywords: 918, senate, all

Summary: The committee heard public testimony on a health insurance/home care nursing provision and on other consumer protection items. Nick Keis and Emily Walters, both parents of medically complex children, testified that commercial health plans had recently begun capping home care nursing as if it were intermittent home health visits, which they said was contrary to Minnesota law and legislative intent dating to 2010. They described severe impacts on their families, including hospitalizations, loss of nursing coverage, strain on waiver budgets, and the risk of children being forced out of the home and into institutions. Representative Bierman echoed that the bill was a straightforward clarification of existing law, not a new mandate or added cost, and a staff member later cited the statutory definition of home care nursing as ongoing, continuous nursing services that cannot be met through intermittent or visit-based care. The committee also discussed the practical difference between home health visits and private duty/home care nursing, with testimony emphasizing that the latter is medically necessary, assessed, and not unlimited in practice. Laura Sales of the Minnesota Attorney General’s Office testified on changes to the Consumer Protection Restitution Fund (CIPRA). She said the fund has begun distributing restitution, starting with consumers harmed by the closure of Woodbury Dental Arts, but that current statutory language limits the office’s flexibility to prorate payments. She asked for an amendment allowing the AGO to distribute available funds more equitably so more eligible consumers can receive some payment, rather than requiring full payment to the oldest claims first. Annette Meeks, representing Citizens Against Gambling Expansion, testified in support of banning sweepstakes gambling in the Commerce Committee omnibus report. She argued that online sweepstakes casinos are an illegal gray-market form of gambling, cited rapid growth and billions in revenue, and said other states have acted through enforcement and legislation to stop them. She urged the committee to include language from Senate File 4474 to clarify state law and prohibit sweepstakes gambling. No votes were taken in the portion of the meeting shown; members mainly asked questions and received testimony.

Transcript Highlights:

• approval process and the secrecy about vaccines from prescriptions, whatever they are, any of the pharmaceutical
• approval process and the secrecy about vaccines from prescriptions, whatever they are, any of the pharmaceutical
• approval process and the secrecy about vaccines from prescriptions, whatever they are, any of the pharmaceutical
• approval process and the secrecy about vaccines from prescriptions, whatever they are, any of the pharmaceutical
• approval process and the secrecy about vaccines from prescriptions, whatever they are, any of the pharmaceutical

Keywords: 1187, senate, all

Transcript Highlights:

• Lieder and Suckla, also Senators Kipp and Rich, concerning the continuation of the Veterinary Pharmaceutical
• and Rich concerning the continuation of the<01:18:12.239><c> Veterinary</c><01:18:12.640><c> Pharmaceutical
• </c><01:18:13.199><c> Advisory</c> the Veterinary Pharmaceutical Advisory the Veterinary Pharmaceutical
• Agencies to repeal<01:18:19.280><c> the</c><01:18:19.440><c> Veterinary</c><01:18:19.840><c> Pharmaceutical
• </c> repeal the Veterinary Pharmaceutical repeal the Veterinary Pharmaceutical Advisory<01:18:20.880>

Keywords: 981, all